Gary Middleton

29.7k citations
179 papers · 9.3k · 5 hit papers · h-index 41

Impact in

  • Oncology top 0.2%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Colorectal Cancer Treatments and Studies 40
    • Cancer Immunotherapy and Biomarkers 28
    • Pancreatic and Hepatic Oncology Research 15
    • Cancer Treatment and Pharmacology 11
    • Lung Cancer Treatments and Mutations 32
    • Gastric Cancer Management and Outcomes 18

Gary Middleton

176 papers receiving 9.0k citations

Gary Middleton's Hit Papers

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies 2015 · 639 citations
6390+6+12Years since publication50010001.5k

Peers

Gary Middleton
Comparison fields: 5 of 123
  • Oncology 4.3k
  • Gastroenterology 578
  • Pulmonary and Respiratory Medicine 3.2k
  • Immunology 1.4k
  • Cancer Research 688
Replace Hans Prenen with:
Hans Prenen Belgium
Takashi Aikou Japan
Kazuhiro Yoshida Japan
Roderich E. Schwarz United States
Michele Orditura Italy
Takenori Ochiai Japan
Hiroki Yamaue Japan
Thilo Hackert Germany
Denis Soulières Canada
Won Ki Kang South Korea
Gary Middleton relative to Hans Prenen Belgium Hans Prenen's profile →
Citations per field
00.5×1.6×
Hans Prenen · 1×
Citations per year

Countries citing papers authored by Gary Middleton

Since Specialization
Citations

This map shows the geographic impact of Gary Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Middleton more than expected).

Fields of papers citing papers by Gary Middleton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Middleton. The network helps show where Gary Middleton may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Middleton Line = papers co-authored together Gary Middleton links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 179 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Hit paper breakdown →
20081773
2
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
Hit paper breakdown →
2008743
3
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Hit paper breakdown →
2015639
4
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Hit paper breakdown →
2013566
5 2011492
6
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hit paper breakdown →
2013419
7 2011278
8 1978165
9 2019145
10 2012138
11 2009134
12 2016129
13 2016125
14 2011124
15 2020116
16 2017114
17 2009100
18 201794
19 201489
20 201484

About Gary Middleton

Gary Middleton is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Immunology, having authored 179 papers that have together received 9.3k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (40 papers), Lung Cancer Treatments and Mutations (32 papers), Cancer Immunotherapy and Biomarkers (28 papers), Cancer Genomics and Diagnostics (24 papers), Gastric Cancer Management and Outcomes (18 papers), Pancreatic and Hepatic Oncology Research (15 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal and Anal Carcinomas (10 papers). The work is most often cited by research in Oncology (4.3k citations), Gastroenterology (578 citations), Pulmonary and Respiratory Medicine (3.2k citations), Immunology (1.4k citations) and Cancer Research (688 citations). Gary Middleton has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Leisha A. Emens, David Cunningham, Fareeda Y. Coxon, Timothy Iveson, A. Norman, Naureen Starling, M. Nicolson, Sheela Rao, J. Oates and Francis Daniel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Nuclear Medicine Communications and Cancer Immunology Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact